Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent Itraconazole

  • Lees R
  • Lees A
135Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

Abstract

To the Editor: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, widely prescribed to treat hypercholesterolemia, are clearly effective and are associated with reductions in mortality from coronary disease and overall mortality.1 Toxic effects on skeletal muscle, which may range from diffuse myalgia to severe rhabdomyolysis, are a known side effect of these drugs.2 Interactions of HMG-CoA reductase inhibitors with cyclosporine, and less often with gemfibrozil and niacin, increase the risk of rhabdomyolysis.2 We report a case of severe rhabdomyolysis from the coadministration of lovastatin, niacin, and itraconazole. A 63-year-old woman with familial hypercholesterolemia and a previous myocardial infarction who had. © 1995, Massachusetts Medical Society. All rights reserved.

Cite

CITATION STYLE

APA

Lees, R. S., & Lees, A. M. (1995). Rhabdomyolysis from the Coadministration of Lovastatin and the Antifungal Agent Itraconazole. New England Journal of Medicine, 333(10), 664–665. https://doi.org/10.1056/nejm199509073331015

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free